The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease

Abubakr A. Bajwa, Adil Shujaat, Minal Patel, Colleen Thomas, Franck Rahaghi, Charles Dwayne Burger

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The primary aim was to explore the safety and tolerability of inhaled treprostinil when used in patients with pulmonary hypertension (PH) with concomitant chronic obstructive pulmonarydisease (COPD). Patients with a diagnosis of pre-capillary PH (defined as pulmonary artery mean pressure of ≥ 25 mmHg and pulmonary artery wedge pressure or left ventricular end diastolic pressure of ≤ 15 mmHg) who were being initiated on inhaled treprostinil and had concomitant COPD (defined as FEV1/FVC ratio ≤ 70% with FEV1 ≥ 40% predicted) were considered for inclusion in this pilot study. Assessments included adverse events, physical exam, World Health Organization (WHO) functional class, 6-minute walk test (6MWT), modified Borg dyspnea score, and concomitant medication. At baseline and week 16 St. George’s Respiratory Questionnaire (SGRQ), arterial blood gas (ABG), and pulmonary function test (PFT) were assessed. The median age was 65 years (age range, 56–80 years) and five patients (56%) were men. Among the nine patients, a majority had an increase in 6MWT from baseline to week 16 (median change, 19 m). Only three of the nine patients (33%) had an increase in A-a gradient at week 16 (median change, –7). There was no difference in any of the following: arterial blood gases, WHO functional class, 6MWT results, or SGRQ scores from baseline to week 16. There was a statistically significant decline in several of the PFT measures, including FEV1 (median change, –0.18 L; P = 0.004; median change, –7% of predicted; P = 0.016), FVC (median change, –0.23 L; P = 0.027), and diffusion capacity for carbon monoxide (DLCO) (median change, –5% of predicted; P = 0.023). The small number of patients limits firm conclusions; however, inhaledtreprostinil did not seem to adversely impact oxygenation in the majority of the study patientswith pre-capillary PH and COPD. While there may have an adverse impact on some pulmonaryfunction parameters, the clinical significance is unclear.

Original languageEnglish (US)
Pages (from-to)82-88
Number of pages7
JournalPulmonary Circulation
Volume7
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Pulmonary Hypertension
Chronic Obstructive Pulmonary Disease
Safety
Respiratory Function Tests
Gases
Pulmonary Wedge Pressure
Carbon Monoxide
Dyspnea
Pulmonary Artery
treprostinil
Blood Pressure
Pressure
Walk Test

Keywords

  • Chronic obstructive pulmonary disease (COPD)
  • Inhaledtreprostinil
  • Pulmonary hypertension
  • Safety
  • Tolerability

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease. / Bajwa, Abubakr A.; Shujaat, Adil; Patel, Minal; Thomas, Colleen; Rahaghi, Franck; Burger, Charles Dwayne.

In: Pulmonary Circulation, Vol. 7, No. 1, 01.01.2017, p. 82-88.

Research output: Contribution to journalArticle

Bajwa, Abubakr A. ; Shujaat, Adil ; Patel, Minal ; Thomas, Colleen ; Rahaghi, Franck ; Burger, Charles Dwayne. / The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease. In: Pulmonary Circulation. 2017 ; Vol. 7, No. 1. pp. 82-88.
@article{cdb93cf54877418e82d8e86354ccc7a5,
title = "The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease",
abstract = "The primary aim was to explore the safety and tolerability of inhaled treprostinil when used in patients with pulmonary hypertension (PH) with concomitant chronic obstructive pulmonarydisease (COPD). Patients with a diagnosis of pre-capillary PH (defined as pulmonary artery mean pressure of ≥ 25 mmHg and pulmonary artery wedge pressure or left ventricular end diastolic pressure of ≤ 15 mmHg) who were being initiated on inhaled treprostinil and had concomitant COPD (defined as FEV1/FVC ratio ≤ 70{\%} with FEV1 ≥ 40{\%} predicted) were considered for inclusion in this pilot study. Assessments included adverse events, physical exam, World Health Organization (WHO) functional class, 6-minute walk test (6MWT), modified Borg dyspnea score, and concomitant medication. At baseline and week 16 St. George’s Respiratory Questionnaire (SGRQ), arterial blood gas (ABG), and pulmonary function test (PFT) were assessed. The median age was 65 years (age range, 56–80 years) and five patients (56{\%}) were men. Among the nine patients, a majority had an increase in 6MWT from baseline to week 16 (median change, 19 m). Only three of the nine patients (33{\%}) had an increase in A-a gradient at week 16 (median change, –7). There was no difference in any of the following: arterial blood gases, WHO functional class, 6MWT results, or SGRQ scores from baseline to week 16. There was a statistically significant decline in several of the PFT measures, including FEV1 (median change, –0.18 L; P = 0.004; median change, –7{\%} of predicted; P = 0.016), FVC (median change, –0.23 L; P = 0.027), and diffusion capacity for carbon monoxide (DLCO) (median change, –5{\%} of predicted; P = 0.023). The small number of patients limits firm conclusions; however, inhaledtreprostinil did not seem to adversely impact oxygenation in the majority of the study patientswith pre-capillary PH and COPD. While there may have an adverse impact on some pulmonaryfunction parameters, the clinical significance is unclear.",
keywords = "Chronic obstructive pulmonary disease (COPD), Inhaledtreprostinil, Pulmonary hypertension, Safety, Tolerability",
author = "Bajwa, {Abubakr A.} and Adil Shujaat and Minal Patel and Colleen Thomas and Franck Rahaghi and Burger, {Charles Dwayne}",
year = "2017",
month = "1",
day = "1",
doi = "10.1086/689291",
language = "English (US)",
volume = "7",
pages = "82--88",
journal = "Pulmonary Circulation",
issn = "2045-8932",
publisher = "University of Chicago Press",
number = "1",

}

TY - JOUR

T1 - The safety and tolerability of inhaled treprostinil in patients with pulmonary hypertension and chronic obstructive pulmonary disease

AU - Bajwa, Abubakr A.

AU - Shujaat, Adil

AU - Patel, Minal

AU - Thomas, Colleen

AU - Rahaghi, Franck

AU - Burger, Charles Dwayne

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The primary aim was to explore the safety and tolerability of inhaled treprostinil when used in patients with pulmonary hypertension (PH) with concomitant chronic obstructive pulmonarydisease (COPD). Patients with a diagnosis of pre-capillary PH (defined as pulmonary artery mean pressure of ≥ 25 mmHg and pulmonary artery wedge pressure or left ventricular end diastolic pressure of ≤ 15 mmHg) who were being initiated on inhaled treprostinil and had concomitant COPD (defined as FEV1/FVC ratio ≤ 70% with FEV1 ≥ 40% predicted) were considered for inclusion in this pilot study. Assessments included adverse events, physical exam, World Health Organization (WHO) functional class, 6-minute walk test (6MWT), modified Borg dyspnea score, and concomitant medication. At baseline and week 16 St. George’s Respiratory Questionnaire (SGRQ), arterial blood gas (ABG), and pulmonary function test (PFT) were assessed. The median age was 65 years (age range, 56–80 years) and five patients (56%) were men. Among the nine patients, a majority had an increase in 6MWT from baseline to week 16 (median change, 19 m). Only three of the nine patients (33%) had an increase in A-a gradient at week 16 (median change, –7). There was no difference in any of the following: arterial blood gases, WHO functional class, 6MWT results, or SGRQ scores from baseline to week 16. There was a statistically significant decline in several of the PFT measures, including FEV1 (median change, –0.18 L; P = 0.004; median change, –7% of predicted; P = 0.016), FVC (median change, –0.23 L; P = 0.027), and diffusion capacity for carbon monoxide (DLCO) (median change, –5% of predicted; P = 0.023). The small number of patients limits firm conclusions; however, inhaledtreprostinil did not seem to adversely impact oxygenation in the majority of the study patientswith pre-capillary PH and COPD. While there may have an adverse impact on some pulmonaryfunction parameters, the clinical significance is unclear.

AB - The primary aim was to explore the safety and tolerability of inhaled treprostinil when used in patients with pulmonary hypertension (PH) with concomitant chronic obstructive pulmonarydisease (COPD). Patients with a diagnosis of pre-capillary PH (defined as pulmonary artery mean pressure of ≥ 25 mmHg and pulmonary artery wedge pressure or left ventricular end diastolic pressure of ≤ 15 mmHg) who were being initiated on inhaled treprostinil and had concomitant COPD (defined as FEV1/FVC ratio ≤ 70% with FEV1 ≥ 40% predicted) were considered for inclusion in this pilot study. Assessments included adverse events, physical exam, World Health Organization (WHO) functional class, 6-minute walk test (6MWT), modified Borg dyspnea score, and concomitant medication. At baseline and week 16 St. George’s Respiratory Questionnaire (SGRQ), arterial blood gas (ABG), and pulmonary function test (PFT) were assessed. The median age was 65 years (age range, 56–80 years) and five patients (56%) were men. Among the nine patients, a majority had an increase in 6MWT from baseline to week 16 (median change, 19 m). Only three of the nine patients (33%) had an increase in A-a gradient at week 16 (median change, –7). There was no difference in any of the following: arterial blood gases, WHO functional class, 6MWT results, or SGRQ scores from baseline to week 16. There was a statistically significant decline in several of the PFT measures, including FEV1 (median change, –0.18 L; P = 0.004; median change, –7% of predicted; P = 0.016), FVC (median change, –0.23 L; P = 0.027), and diffusion capacity for carbon monoxide (DLCO) (median change, –5% of predicted; P = 0.023). The small number of patients limits firm conclusions; however, inhaledtreprostinil did not seem to adversely impact oxygenation in the majority of the study patientswith pre-capillary PH and COPD. While there may have an adverse impact on some pulmonaryfunction parameters, the clinical significance is unclear.

KW - Chronic obstructive pulmonary disease (COPD)

KW - Inhaledtreprostinil

KW - Pulmonary hypertension

KW - Safety

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=85034575501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034575501&partnerID=8YFLogxK

U2 - 10.1086/689291

DO - 10.1086/689291

M3 - Article

AN - SCOPUS:85034575501

VL - 7

SP - 82

EP - 88

JO - Pulmonary Circulation

JF - Pulmonary Circulation

SN - 2045-8932

IS - 1

ER -